Activity
Amylyx’s ALS Treatment Relyvrio Disappoints in Phase III PHOENIX Study, Company Considering Market Withdrawal
Amylyx, Relyvrio, ALS, Failure, Phase III PHOENIX Study, Market Withdrawal, Clinical Trial, Placebo, No Statistical Significance
Sandoz Pays $265 Million to Resolve Partial Antitrust Claims in Price Fixing Lawsuits
sandoz, Settlement and Resettlement, Litigation
Improving Amylyx’s ALS Drug Relyvrio: Taste Masking and Withdrawal
Amylyx, ALS, Relyvrio, Taste Masking, Withdrawal, Patent Life
Novavax Secures $400 Million Settlement with Gavi to Resolve COVID-19 Vaccine Contract Dispute
Gavi, Novavax, Settlement and Resettlement
Alvotech and Teva Settle with Johnson & Johnson for Stelara Biosimilar AVT04 in the US
Alvotech, Teva, Settlement and Resettlement, AVT04, United States
After Incyte’s commercial buy, Novartis shells out 2.7B for cancer specialist MorphoSys
Importal, MorphoSys, Acquisition (action), Incyte
Updated: Novo Holdings pays $16.5B to take Catalent private and sells three manufacturing sites to Novo Nordisk
Holdings, Nordisk, deal, Acquisition (action), Investments
Sanofi gains AATD hopeful with $1.7-billion deal for Inhibrx
sanofi, Inhibrx, Acquisition (action), alpha 1-Antitrypsin Deficiency, Market
Bristol Myers’ Opdivo fails part two of post-kidney cancer surgery test as competitor Merck touts new survival data
Bristol, Myers, Opdivo, post-kidney cancer surgery test, Continuance of life